FilingReader Intelligence
Junshi Bio's cancer drug advances in China approval
August 8, 2025 at 05:03 PM UTC•By FilingReader AI
Shanghai Junshi Biosciences Co announced China's drug regulator accepted its supplemental application for toripalimab combined with disitamab vedotin as first-line treatment for advanced urothelial carcinoma.
The RC48-C016 study showed the combination significantly improved progression-free survival and overall survival versus standard chemotherapy.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1877•Hong Kong Exchange
News Alerts
Get instant email alerts when Junshi BIO publishes news
Free account required • Unsubscribe anytime